Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
11,025 total articles
Denali Therapeutics announced FDA accelerated approval and U.S. commercial launch of AVLAYAH for Hunter syndrome, the first medicine leveraging the transferrin receptor to cross the blood-brain barrier. The company reported progress across its pipeline targeting Alzheimer's, frontotemporal dementia, Sanfilippo syndrome, Pompe disease, and Parkinson…
Annexon, Inc. reported its first quarter 2026 financial results and detailed significant progress and upcoming milestones across its neuroinflammatory disease therapy portfolio. Key upcoming catalysts include topline Phase 3 data for vonaprument targeting Geographic Atrophy (GA) expected in Q4 2026, regulatory review of tanruprubart for Guillain-Ba…
SIGA Technologies announced its financial results for Q1 2026, reporting net losses but highlighted planned deliveries of $13 million oral TPOXX to an international customer and $26 million IV TPOXX to the U.S. Government Strategic National Stockpile by Q3 2026. The company also secured an exclusive license agreement for oral TPOXX commercializatio…
Akamai Technologies reported first quarter 2026 revenue of $1.074 billion, a 6% increase year-over-year driven primarily by 40% growth in Cloud Infrastructure Services and 11% growth in security revenue. The company announced a $1.8 billion seven-year commitment from a leading U.S.-based frontier model provider in AI, validating Akamai's position i…
Senseonics Holdings, Inc. reported robust first quarter 2026 financial results with revenue growing 87% year-over-year to $11.7 million. The company highlighted significant commercial progress, including the US launch of Eversense 365 and expansion into Europe. They raised over $100 million in equity and debt financing to support ongoing product co…
Voyager Therapeutics announced its first quarter 2026 financial results and operational progress, highlighting completion of IND-enabling toxicology studies for its tau silencing gene therapy VY1706, with first-in-human dosing expected in the second half of 2026 for Alzheimer's disease. The company maintains a strong cash position of $172 million, …
BridgeBio Pharma reported first quarter 2026 financial results highlighting $194.5 million in total revenues, primarily driven by $180.6 million from U.S. sales of its ATTR-CM drug Attruby. The company continues to see strong commercial traction for Attruby, including new approval in Brazil. It has submitted its first NDA for BBP-418 (LGMD2I/R9) an…
Xenon Pharmaceuticals announced positive topline Phase 3 data from the X-TOLE2 study for azetukalner in focal onset seizures, leading to an anticipated New Drug Application submission to the FDA in Q3 2026. The company continues enrollment in additional Phase 3 trials for epilepsy and neuropsychiatric indications and advances early-stage pain candi…
Clearway Energy, Inc. reported Q1 2026 results with a net loss of $68 million, Adjusted EBITDA of $257 million, and reassured full-year 2026 CAFD guidance of $470 to $510 million. The company progressed significant growth initiatives, including completion of the Honeycomb Phase 1 battery storage facilities, acquisition of the Cardinal solar portfol…
Prairie Operating Co., an independent energy company focused on oil and natural gas development in the Denver-Julesburg Basin, will release its first quarter 2026 financial and operating results on May 14, 2026, followed by a conference call on May 15. The company invites analysts and investors to participate as it provides updates on recent develo…
Tectonic Therapeutic announced its Q1 2026 financial results highlighting significant clinical progress with TX45 and TX2100 drug candidates targeting pulmonary hypertension and hereditary hemorrhagic telangiectasia (HHT). Key milestones include near completion of patient enrollment in TX45 APEX Phase 2 trial, initiation of TX45 ALPINE Phase 2 tria…
Celldex has successfully completed enrollment for its Phase 3 studies in chronic spontaneous urticaria (CSU) six months ahead of schedule, with topline data expected in Q4 2026 and a planned BLA submission in 2027. Ongoing studies include Phase 3 trials for cold urticaria and symptomatic dermographism, and a Phase 1 study of CDX-622 in asthma. The …
Bluejay Diagnostics provided a Q1 2026 update highlighting progress in clinical enrollment, manufacturing readiness, and regulatory strategy for its Symphony IL-6 test aimed at rapid sepsis patient monitoring. The company enrolled approximately 680 patients in its pivotal SYMON-II study, advanced manufacturing with contract manufacturer Sanyoseiko,…
Quest Resource Holding Corporation announced its Q1 2026 financial results showing a 4.8% sequential revenue increase and 6.1% rise in gross profit from Q4 2025, despite year-over-year declines. The company onboarded new customers, including a large quick-service restaurant franchisee, and refinanced debt to reduce interest expenses. Quest focused …
Serve Robotics announced robust first quarter 2026 results with revenue of $3.0 million, up 238% sequentially and 578% year-over-year, reflecting expansion across delivery and healthcare robotics following the acquisition of Diligent Robotics. The company expanded operations to 44 cities in 14 states, grew its robot fleet to approximately 2,000 uni…
Amneal Pharmaceuticals reported a solid start to 2026 with a 4% increase in Q1 net revenue to $723 million and a 411% jump in net income to $62 million compared to Q1 2025. Adjusted EBITDA rose 19% to $202 million, driven by strong performance across its Specialty and Affordable Medicines segments. The company also reaffirmed its previously raised …
Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company focused on Alzheimer’s disease therapeutics, announced management's participation in a fireside chat at the Bank of America Securities 2026 Health Care Conference. The company is advancing its lead drug candidate, sabirnetug (ACU193), targeting toxic amyloid beta oligomers, currentl…
INmune Bio Inc., a NASDAQ-listed clinical-stage immunology company, announced a reduced net loss of $5.4 million for Q1 2026 versus $9.7 million in Q1 2025, reflecting lower R&D expenses. Key milestones include UK MHRA pre-submission for CORDStrom™, anticipated regulatory filings in the UK, EU, and US later this year, new Phase 2 imaging data for X…
Assembly Biosciences announced steady progress in Q1 2026, completing Phase 1b studies for two herpesvirus drug candidates, completing toxicology studies for a hepatitis delta virus candidate, and preparing for a Phase 2 initiation later in 2026. The company also reported a strong cash position projected to fund operations into 2028, despite a net …
E-Power Inc. (NASDAQ: EPOW) announced the grant of a patent for a double-layer coated silicon-carbon composite material, a critical advancement in developing next-generation solid-state batteries. This patented technology enhances battery stability and capacity, reinforcing E-Power's leadership in high-density energy storage solutions and industria…
Magnera Corporation (NYSE: MAGN) has announced its participation in the 2026 Barclays 30th Annual Leveraged Finance Conference in Austin, Texas, where senior executives will meet with institutional investors to discuss the company's strategies and operations. The company, which serves a wide range of industries with material solutions, emphasized i…
HII, the largest U.S. military shipbuilder, received the prestigious Business Group on Health's 2026 Best Employers Award for Excellence in Health Care Value, highlighting its innovative employee benefits focused on prevention, clinical outcomes, and long-term savings. This marks the third consecutive year HII has been recognized for its commitment…
Toll Brothers, a leading US luxury home builder, announced the launch of its new community, Monterey at Lakewood Ranch - Egret Collection, set to open in summer 2026. The community will feature upscale single-family homes with extensive amenities, located within the prestigious Lakewood Ranch area in Florida, with prices starting at $1.4 million.
Fortis Inc. shareholders unanimously approved the election of 12 directors, reappointment of Deloitte LLP as auditors, and the non-binding advisory vote on executive compensation at the 2026 Annual Meeting. The corporation is a leading North American regulated electric and gas utility with operations across Canada, the U.S., and the Cayman Islands.
Lemonade announced the launch of its renters insurance offering in West Virginia, expanding its digital-first, customizable coverage to renters across the state. The company emphasizes affordability, flexibility, and a seamless app-based customer experience, aiming to grow its U.S. market presence further.
